Evaxion teases 67% response rate in PhI metastatic melanoma trial

Paul Schloesser

Associate Editor

Evaxion Biotech said eight of 12 patients with metastatic melanoma who received a combination of the lead candidate and an unnamed checkpoint inhibitor had a …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Evaxion teases 67% response rate in PhI metastatic melanoma trial

Paul Schloesser

Associate Editor

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

CBER's deputy director departs as staff shakeup continues

Will CRISPR matter?

FDA approves first drug to treat ultra-rare lipid storage disease

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Evax­ion teas­es 67% re­sponse rate in PhI metasta­t­ic melanoma tri­al

Associate Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Evaxion teases 67% response rate in PhI metastatic melanoma trial